# Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection

> **NCT04267809** · PHASE2 · COMPLETED · sponsor: **Singapore General Hospital** · enrollment: 32 (actual)

## Conditions studied

- Endoplasmic Reticulum Stress
- Viral Infection
- Yellow Fever

## Interventions

- **DRUG:** Metformin Hydrochloride
- **DRUG:** Calcium and Vitamin D

## Key facts

- **NCT ID:** NCT04267809
- **Lead sponsor:** Singapore General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-22
- **Primary completion:** 2023-07-31
- **Final completion:** 2023-07-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04267809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04267809, "Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04267809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*